Replies to post #1253 on Medizone Intl. (fka MZEIQ)

[goforthebet]

exactly Ben: Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun

SAN FRANCISCO, May 6 /PRNewswire-FirstCall/ -- Medizone (Pink Sheets: MZEI) is pleased to announce the commencement of the first in a series of trials designed to confirm that the Medizone AsepticSure(TM) Hospital Sterilization System can rapidly eliminate hospital-based bacterial pathogens known to be responsible for the growing number of deaths and serious infections currently plaguing the healthcare system world wide.

Dr. Dick zoutman, an internationally recognized expert in Medical Microbiology and hospital infections, is leading these trials. Medizone International's Director of Medical Affairs, Dr. Michael E. Shannon observed, "This is an exciting time for our medical engineering group. The equipment is superbly designed with full computer control of all test parameters and hence, we are confident that the entire series of studies will be GLP compliant.

If these trials successfully demonstrate that our equipment and protocols are fully effective at eliminating the bacteria being tested, as we anticipate, the results will constitute a powerful signal to the health care community that a safe and inexpensive solution will soon be available to effectively address a problem which last year resulted in over 60,000 hospital acquired infectious disease deaths in North America alone."


"This project," added Dr. zoutman, "has the potential of saving thousands of lives and hundreds of millions of dollars for hospital operating systems." Medizone expects to release the results of these first trials in June, following the filing of new patent applications.

[goforthebet]

Dr. Dick Zoutman

M.D., FRCPC, Professor

Kingston General Hospital
Department of Pathology
Infection Control Service

Cross Appointments

Associate Professor of Pathology and of Community Health and Epidemiology

Research Interests

•Epidemiology of antibiotic use in clinical practice, examining the medical and nonmedical factors that influence antibiotic prescribing

•Epidemiology and control of nosocomial (hospital-acquired infections), particularly surgical site infections

•Costs of nosocomial infections


Details of Research Interests

My research centers around the epidemiology of antibiotic use in day to day practice of medicine. I am conducting clinical trials to improve prescribing procedures of antibiotics, and Canadian-wide evaluations of antibiotic use in general hospitals. I am conducting nation wide studies on the resources consumed by nosocomial infections and the efforts of hospitals to prevent nosocomial infections.



Selected Publications

Zoutman, D.E., Pearce, P., McKenzie, M., Taylor, G.D. Surgical wound infections occurring in day surgery patients. Am. J. Inf. Control, 18: 277-282, 1990


Zoutman, D.E., Hulbert, W.C., Pasloske, B.L. et al. The role of polar pili in adherence of Pseudomonas aeruginosa to injured canine tracheal cells: a semiquantitative morphologic study. Scanning Microscopy, 5: 109-126, 1991


Zoutman D, Watterson J, Chau L, Mackenzie T, Djurfeldt M. A Canadian survey of surgical prophylactic antibiotic use: Results of the Canadian antimicrobial utilization in surgery study (CAUSS). Inf Contr Hosp Epidemiol. 1999, 20: 752-755


Zoutman D, McDonald S, Vethanayagam D. Total and attributable costs of surgical wound infections at a Canadian tertiary care center. Inf. Contr. Hosp. Epidemiol. 1998; 19: 254-259


Aoki F, and the Zanamivir Study Group. Impact of zanamivir treatment on productivity, health status and health Resource use in patients with influenza. Pharmacoeconomics. 2000, 17: 187-195

[jim6103]

BenK...."What not everyone here may realize is that Dr. Dick Zoutman, who led the study that the article refers to, is the very same person who is leading Medizone's test trials!"

That is one heck of a tid bit! Thanks for that input. This "story" is beginning to take on real proportions for me. Just like yourself and threw, I am having a very difficult time trying to get my arms around the scope of MZEI's future potential. I am all "ga ga" over another biotech stock that has real promise. The situation here dwarfs that by many logs.

That said, with a successful beta test, I believe that the company will be quickly valued at around a billion dollars market cap. If anyone is having trouble with the pps calculation just take a billion and divide it by the outstanding stock. If you are somewhere around $4, you did good in your computations.

This PPS calculation is by no means a goal or end figure. It is merely a launching point before we get sales figures. The sky is truly the limit on this bugger!...GLTA...Jim